Because the three aptamers recognized maturing granulocytes and monocytes better than CD34(+) early progenitors, we separated AML clinical specimens into three groups: 1) AML non-M3 CD34(+); 2) AML non-M3 CD34(-); and 3) AML M3. Here, CD34 is linked to acute myeloid leukemia.